Urogen Pharma (NASDAQ:URGN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $39.50.

URGN has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. D. Boral Capital restated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Finally, Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th.

Urogen Pharma Stock Performance

Urogen Pharma stock opened at $38.02 on Friday. Urogen Pharma has a 1-year low of $12.89 and a 1-year high of $39.58. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -13.83 and a beta of 1.56. The firm’s fifty day moving average price is $29.84 and its two-hundred day moving average price is $23.88.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. On average, research analysts forecast that Urogen Pharma will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00. Following the transaction, the insider directly owned 129,763 shares of the company’s stock, valued at $4,543,002.63. The trade was a 7.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC lifted its position in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after buying an additional 1,968 shares in the last quarter. Barclays PLC lifted its position in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after buying an additional 2,125 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.